

4th Warsaw Meeting on Secondary and Resistant Hypertension

Satellite symposium to the ESH 27th European Meeting on Hypertension and Cardiovascular Protection in Milan

Warsaw, 20th October 2017

Hotel Bristol, Krakowskie Przedmieście 42/44

Registration 8:00-9:00

Program

Session 1. 9:00-10:30

Treatment of difficult-to-treat and resistant hypertension

Chair: Alberto Morganti, Pierre-Francois Plouin, Andrzej Januszewicz

1. Welcome and introduction
Andrzej Januszewicz (5')
2. Renal denervation 2017 – what we learned from recent clinical trials
Michel Azizi (20')
3. Why aldosterone antagonists are efficient in difficult-to-treat hypertension?
Aleksander Prejbisz (20')
4. Aldosterone antagonists in patients with chronic kidney disease.
Andrzej Więcek (20')
5. Optimal pharmacological treatment – does it exist?
Andrzej Januszewicz (20')

Session 2. 10:30-12:00

Renovascular hypertension in 2017 – focus on fibromuscular dysplasia

Chair: Małgorzata Szczerbo-Trojanowska, Andrzej Tykarski, Andrzej Więcek

1. Renovascular hypertension in 2017 – fibromuscular dysplasia or atherosclerosis?
Andrzej Januszewicz (5')
2. Fibromuscular dysplasia – is it a single disease?
Pierre-Francois Plouin (20')
3. ARCADIA-POL study – landscape of FMD in Poland
Andrzej Januszewicz (20')
4. Case presentations: Different clinical scenarios of FMD
Ewa Warchoł-Celińska, Łukasz Stryczyński, Łukasz Świątłowski (30')
5. Discussion

Coffee break 12:00 – 12:20

Session 3. 12:20 – 13:40

Controversies in the management of primary aldosteronism

Chair: Jacques Lenders, Michel Azizi, Aleksander Prejbisz

1. How to screen patients for primary aldosteronism?
Alberto Morganti (20')
2. Subtype evaluation and follow-up of patients with primary aldosteronism - did SPARTACUS and PASO studies change clinical approach?
- Paolo Mulatero (20')
3. Genetics of primary aldosteronism – the time has come?
- Tracy Williams (20')
4. Case presentations – Primary aldosteronism
Aleksander Prejbisz (10')
Commentary
Expert panel (10')

Session 4 13:40 – 15:20

Management of endocrine hypertension

Chair: Graeme Eisenhofer, Paolo Mulatero, Tomasz Bednarczuk

1. Screening for catecholamine producing tumors – tailoring biochemical methods for different clinical and genetic profiles.
Graeme Eisenhofer (20')
2. Evaluation of incidentaloma – guidelines and reality
Tomasz Bednarczuk (20')
3. Treatment and follow-up of patients with pheochromocytoma and paraganglioma.
- Jacques Lenders (20')
4. Case presentations – Pheochromocytoma and Paraganglioma
Mariola Pęczkowska, (10')
Commentary
Expert panel (10')
5. Case presentations – Cushing disease
Urszula Ambroziak, (10')
Commentary
Expert panel (10')